The Lifestyle Education About Nutrition for Diabetes (Legend) Study
- Conditions
- Type 2 Diabetes
- Interventions
- Behavioral: Moderate-carbohydrate plate-method dietBehavioral: Very low-carbohydrate diet
- Registration Number
- NCT05237128
- Lead Sponsor
- University of Michigan
- Brief Summary
This study is being completed to compare two dietary approaches for participants with type 2 diabetes. This research will test whether a very low-carbohydrate or a plate-method diet better improves outcomes for blood glucose control and body composition for patients with type 2 diabetes that follow one of these approaches for 12 months.
Participants that meet screening and eligibility will be randomized to one of the two diets. In addition to the diet, study specific visits and assessments will be performed at various timepoints.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 180
- diagnosis of type 2 diabetes, with current HbA1c > 6.5% and < 12% (self-reported and then measured at screening)
- ability to speak English (this is a group-based intervention)
- ability to engage in light physical activity
- willingness to be randomized to either type of diet
- unable to provide informed consent
- substance abuse, mental health, cognitive, or medical condition that would, in the opinion of the investigators, make it difficult for the individual to take part in the intervention, may alter key outcomes, or may require important diet modifications and includes conditions such as hypercalcemia or thyroid dysfunction
- pregnant or planning to become pregnant in the next 12 months, or currently breastfeeding (pregnancy and breastfeeding require modifications to the intervention's dietary approaches)
- current use of weight loss medications (this is likely to alter weight outcomes and may alter other measures)
- history of weight loss (bariatric) surgery or plans for bariatric surgery in the next year
- currently enrolled in a weight loss program or have unalterable plans to enroll in one of these programs in the next year
- vegan or vegetarian
- unwilling or unable to participate in study measurements and group classes
- current use of systemic steroids (self-reported in screening survey; oral or IV systemic steroids excluded. Injected steroids may be permitted depending on frequency and timing of injections with regard to lab assessments (minimum of 2 weeks between injection and blood tests))
- weight above 400 pounds (weight limit for dual-energy X-ray absorptiometry (DEXA) scans)
- history of multiple or recent (within the last four years) kidney stones
- currently following a very low-carbohydrate diet
- unwilling to stop an SGLT2 inhibitor medication if the participant were to be randomized to the very low-carbohydrate diet
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Moderate-carbohydrate plate-method diet Moderate-carbohydrate plate-method diet - Very low-carbohydrate diet Very low-carbohydrate diet -
- Primary Outcome Measures
Name Time Method Change in HbA1c 0 to 12 months HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
- Secondary Outcome Measures
Name Time Method Change in Inflammation based on high sensitivity C-reactive protein (hsCRP) 0 to 12 months High-sensitivity C-reactive protein will be measured with nephelometric methods utilizing latex particles coated with CRP monoclonal antibodies and standardized against a CRP reference preparation.
Change in high-density lipoproteins (HDL) 0 to 12 months Change in percent lean body mass on DEXA 0 to 12 months This will be measured by dual-energy X-ray absorptiometry scan
Change in HbA1c 0 to 4 months HbA1c will be measured by standard immunoturbidimetric assay methods and quality control measures at a Clinical Laboratory Improvement Amendments (CLIA) certified lab.
Change in bone mineral density in total hip 0 to 12 months This will be measured by dual-energy X-ray absorptiometry scan
Change in small particle low-density lipoproteins (LDL) 0 to 12 months Change in triglycerides 0 to 12 months Change in percent body fat on DEXA 0 to 12 months This will be measured by dual-energy X-ray absorptiometry scan
Change in bone mineral density in lumbar spine 0 to 12 months This will be measured by dual-energy X-ray absorptiometry scan
Reduction in diabetes medications using medication effect score (MES) 0 to 12 months The medication effect score is a means of assessing the overall intensity of a patient's diabetes pharmacotherapy based on potency and dosages of medications (Alexopoulos et al., 2021).
Change in percent body weight loss 0 to 12 months Change in serum procollagen type I N propeptide (s-PINP) 0 to 12 months Change in serum c-terminal telopeptide of type 1 collagen (s-CTX) 0 to 12 months
Trial Locations
- Locations (2)
University of MIchigan
🇺🇸Ann Arbor, Michigan, United States
The University of California San Francisco (UCSF)
🇺🇸San Francisco, California, United States